Current status and future of antifungal therapy for systemic mycoses.

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Since the 1950s there has been an increase in the incidence of invasive fungal disease. The first successful systemically administered antifungal drug, amphotericin B, was introduced in the 1950s and, until very recently, was considered the best therapeutic drug for severe mycoses. The development of new antifungals to treat systemic disease has been slow compared to that of antibacterial compounds, with the introduction of only a single new class of drugs over the past 20 years. This review discusses the antifungal drugs that are clinically in use and summarizes interesting new applications and patents from the US Patent and Trademark Office.

Original languageEnglish (US)
Pages (from-to)75-84
Number of pages10
JournalRecent patents on anti-infective drug discovery
Issue number1
StatePublished - Jan 2006

ASJC Scopus subject areas

  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Current status and future of antifungal therapy for systemic mycoses.'. Together they form a unique fingerprint.

Cite this